These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Oder E; Safo MK; Abdulmalik O; Kato GJ Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087 [TBL] [Abstract][Full Text] [Related]
3. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies. Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104 [TBL] [Abstract][Full Text] [Related]
4. The delay time in sickle cell disease after 40 years: A paradigm assessed. Ferrone FA Am J Hematol; 2015 May; 90(5):438-45. PubMed ID: 25645011 [TBL] [Abstract][Full Text] [Related]
5. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization. Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702 [TBL] [Abstract][Full Text] [Related]
6. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia. Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease. Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508 [TBL] [Abstract][Full Text] [Related]
18. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J; N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090 [TBL] [Abstract][Full Text] [Related]
19. Established and experimental treatments for sickle cell disease. De Franceschi L; Corrocher R Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275 [TBL] [Abstract][Full Text] [Related]
20. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Rodgers GP Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]